Related Experiment Video

Updated: May 5, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

6.9K

The Neurotoxin l-Methyl-4-Phenyl-l,2,3,6-Tetrahydropyridine (MPTP): A Key to Parkinson's Disease?

I Irwin1

  • 1Institute for Medical Research, 2260 Clove Drive, San Jose, California, 95128.

Pharmaceutical Research
|November 26, 2013
PubMed

Insights

The neurotoxin l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes irreversible parkinsonism by selectively killing substantia nigra neurons. Studying MPTP

Area of Science:

  • Neuroscience
  • Toxicology
  • Neurology

Background:

  • Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor deficits.
  • The neurotoxin MPTP induces parkinsonism, offering a model for PD research.
  • MPTP selectively destroys dopaminergic neurons in the substantia nigra pars compacta.

Purpose of the Study:

  • To review the effects and mechanisms of MPTP neurotoxicity.
  • To explore MPTP's potential in understanding Parkinson's disease pathology.
  • To summarize current research on MPTP's biotransformation and action.

Main Methods:

  • Review of existing scientific literature on MPTP.
  • Analysis of studies detailing MPTP's effects on primate and human models.
  • Discussion of biochemical pathways involved in MPTP toxicity.

Main Results:

  • MPTP is a potent inducer of chronic, irreversible parkinsonism.
  • MPTP-induced syndrome in primates closely mimics idiopathic Parkinson's disease.
  • MPTP selectively targets dopaminergic neurons in the substantia nigra.

Conclusions:

  • Understanding MPTP's mechanism of action is crucial for elucidating PD pathogenesis.
  • MPTP serves as a valuable tool for preclinical research in Parkinson's disease.
  • Further research into MPTP's biotransformation and cellular effects is warranted.

More Related Videos

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

17.1K
The 6-hydroxydopamine Rat Model of Parkinson's Disease08:10

The 6-hydroxydopamine Rat Model of Parkinson's Disease

Published on: October 27, 2021

12.7K

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
34
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
36